Administer 1ml intradermally during luteal phase (day 18-28) to counteract androgen-driven sebum production. Clinical data shows 50% reduction in cyclic breakouts.
Androgen Receptor
A Los Angeles beauty clinic encountered a classic case: 26-year-old client developed cystic acne premenstrually, traditional antibiotic treatment failed for 3 months. Tests revealed 38% higher androgen receptor (AR) activity in hair follicle sebaceous units versus normal, explaining recurrent hormonal acne.
Rejuran’s polynucleotide components directly regulate AR signaling pathways. When receptors activate by androgens, they trigger sebum overproduction and abnormal keratinization. Data shows 42% AR gene expression reduction after 3 consecutive injections (Source: 2024 International Journal of Dermatology Research No.IS-562). Compared to isotretinoin, this mechanism avoids systemic hormone disruption, better suits patients with hyperandrogenism signs (hirsutism, alopecia).
Skincare expert Emma states: “90% adult female acne relates to hormonal fluctuations, but 80% anti-acne products only target surface microbiota.”
| Treatment | Action Level | Relapse Rate (6mo) |
|---|---|---|
| Rejuran+Laser Therapy | Gene Expression Regulation | 22% |
| Contraceptive Pill Alone | Systemic Hormone Suppression | 49% |
| Salicylic Acid Peels | Keratinocyte Turnover | 78% |
Menstrual Cycle
Manhattan dermatology clinics tracked 200 users’ acne patterns, 68% inflammatory peaks occur late luteal phase (5-7 days premenstrual). Rising progesterone stimulates AR receptors while estrogen plunge weakens skin anti-inflammatory capacity.
Rejuran injections require three critical windows:
- Mid-Follicular Phase (Day 7-10 post-menstruation): Repair basement membrane damage
- Ovulation Phase (Day 14): Strengthen skin barrier
- Luteal Phase (10 days premenstrual): Suppress inflammatory factors
UC lab found polynucleotides injected during luteal phase persist 27% longer, better neutralize IL-6/TNF-α. Avoid menstrual cycle injections—increased vascular permeability risks bruising (Ref: ICSC-045 safety protocol).
Contraceptives
Dallas endocrinologists use combination therapy: COCP (Combined Oral Contraceptive Pill) with Rejuran. COCP reduces free testosterone; Rejuran repairs hormone-induced dermal damage. Caution: Drospirenone-containing pills increase water retention, raising post-injection edema risk 15%.
| Contraceptive Type | Androgen Suppression | Rejuran Compatibility |
|---|---|---|
| Ethinylestradiol + Norgestimate | 62% | 72-hour injection interval |
| Ethinylestradiol + Drospirenone | 71% | Low-sodium diet peri-injection |
| Progestogen-Only Pill (POP) | 38% | No interval needed |
Florida clinic mishap: Undisclosed contraceptive use caused persistent erythema post-injection. Investigation revealed ethinylestradiol overdose caused metabolic conflict (Case No.CA-112).
Endocrinology
Chicago Medical Center mandates three tests for hormonal acne: â‘ Serum DHEA-S â‘¡ Free Testosterone Index â‘¢ SHBG Levels
When SHBG <25nmol/L, Rejuran requires soy isoflavones. Isoflavones boost SHBG 27%±5%, reducing active androgen stimulation. Caution: Soy allergy requires patch testing (FDA Cosmetic File CT-2205).
Relapse Prediction
Miami AI Skin Monitoring predicts relapse via: 1. Pore shrinkage <30% (42-day VISIA) 2. Premenstrual erythema expansion >15% 3. Sebaceous gland density >120/cm²
Machine learning analysis shows 83% relapse probability within 6mo when all three indicators coexist. Recommended protocol: Shorten injection intervals from 4 to 3 weeks, combine with LED red light (Patent US2024100XXXXX).
Long-Term Tracking
Boston Medical Group 5-year data: – Maintenance Group (3-4 annual injections): 92% acne scar reduction – Intermittent Group (≤1 annual): 18% annual collagen regeneration decline – Discontinued Group: Dermal thickness reverts to baseline at 24 months
Over-treatment alert: New York client received 8 injections in 12 months, causing 41% fibroblast activity reduction. Current standards cap annual treatments at 6 (Clinical Report CR-8852).